In addition, throughout the experiments of the three CRC xenotransplantation models, no toxicities were observed in the HER2 CAR-T group, and the overall survival time of HER2 CAR-T cells-treated mice was significantly prolonged, confirming the powerful anti-tumor effect of HER2 CAR-T on CRC and the safety of its clinical application. This evidence concerns the gene ERBB2 and neoplasm.